Phase 2 Vitiligo Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to communicate clearly with the research team, understand what the trial involves including its risks, and are willing to follow all study requirements and sign a consent form before anything begins.
• People who are aged 18 to 65 years old at the time of signing the consent form, of any gender.
• People who have been clinically diagnosed with non-segmental vitiligo.
• People whose vitiligo meets specific severity measurements (called F-VASI ≥ 0.5 and T-VASI ≥ 5) at both the screening and baseline visits, and whose condition is either currently active (spreading or showing new patches in the past 6 months) or stable (no signs of recent change) — (confirm with trial site for exact measurements).
• People who agree to use effective contraception from the time of signing the consent form until 3 months after the last dose of the study drug; male participants must also agree not to donate sperm during the study and for 3 months after the last dose.
• Women who could become pregnant must have a negative pregnancy blood test at screening and must not be breastfeeding; women who cannot become pregnant must either have had a permanent sterilisation procedure or be postmenopausal (no periods for more than 12 months for reasons other than illness, and for those under 60, a specific hormone level must be confirmed by a blood test).

Who may not be able to join:

• People who have received certain targeted drug therapies or biological medicines within 12 weeks before the baseline visit (or longer, depending on the specific drug).
• People who have received light-based treatments such as UVB therapy, PUVA, excimer laser, other laser treatments, or indoor tanning within 12 weeks before the baseline visit.
• People who have taken certain whole-body (systemic) treatments within 4 weeks before the baseline visit, including immune-suppressing or immune-modifying drugs, systemic Chinese herbal or traditional medicines, or other systemic vitiligo treatments.
• People who have used certain skin (topical) treatments within 2 weeks before the baseline visit, including steroid creams, calcineurin inhibitor creams, PDE-4 inhibitor creams, vitamin D3 creams, topical Chinese herbal preparations, or other topical vitiligo treatments.
• People who have ever had permanent skin-lightening treatment (such as monobenzone or phenol) for vitiligo or other pigment-related conditions.
• People who have previously had a melanocyte-keratinocyte transplant procedure or any other surgical treatment for vitiligo.
• People who have taken strong medications known to significantly affect how the liver processes certain drugs (strong CYP3A inhibitors or inducers) within 2 weeks before the baseline visit.
• People who have taken long-acting blood-thinning medications (such as warfarin or clopidogrel) within 4 weeks before the baseline visit, or who need to continue taking blood thinners during the study (low-dose aspirin at or below 100 mg per day is an exception).
• People who have received or plan to receive a live or live-attenuated vaccine within 4 weeks before the baseline visit, or at any point during the study including at least 4 weeks after the last dose of the study drug.
• People who have taken part in another clinical trial involving an experimental drug within 4 weeks before the baseline visit (or longer depending on the drug), or an experimental medical device trial within 3 months before the baseline visit.

Important: Always verify eligibility with the trial site directly before applying.